文献速递神经技术与安全MR

新型大环状对比剂钆匹醇在中枢神经系统MRI中的剂量探索研究

Dose Finding Study of Gadopiclenol, a New Macrocyclic Contrast Agent, in MRI of Central Nervous System.
PubMed 文献 · Invest Radiol · 2020-01-01

这项IIb期国际多中心双盲随机对照交叉研究纳入272例已知或高度怀疑血脑屏障破坏的中枢神经系统病灶患者,比较钆匹醇4个剂量(0.025、0.05、0.1、0.2 mmol/kg)与钆贝葡胺0.1 mmol/kg的对比噪声比。结果显示钆匹醇0.1和0.2 mmol/kg的CNR较钆贝葡胺0.1 mmol/kg增加超过30%(P≤0.0007),0.05 mmol/kg与钆贝葡胺0.1 mmol/kg CNR相似;作者结论认为0.05和0.1 mmol/kg两个剂量可考虑用于后续III期研究。

要点

  • 钆匹醇0.1和0.2 mmol/kg的CNR较钆贝葡胺0.1 mmol/kg增加超过30%(P≤0.0007)。
  • 钆匹醇0.05 mmol/kg与钆贝葡胺0.1 mmol/kg的CNR相似,差异无统计学意义。
  • 3名读者主要对钆匹醇0.1 mmol/kg图像表达总体诊断偏好或无偏好。

关键影像表现/征象

  • 病灶显示变量平均评分(尤其病灶对比增强)在钆匹醇0.1和0.2 mmol/kg时倾向于高于钆贝葡胺。
  • 3名读者主要对钆匹醇0.1 mmol/kg图像表达总体诊断偏好(分别占45.3%、50.9%、86.8%)或无偏好(分别占49.1%、49.1%、9.4%)。
  • 2名读者对钆贝葡胺图像表达偏好,分别占3.8%和5.7%。
  • 钆匹醇0.05 mmol/kg与钆贝葡胺比较时,主要表达无偏好。

诊断标准与关键数值

  • 主要终点为对比噪声比(CNR):钆匹醇0.2和0.1 mmol/kg在所有读者中均优于钆贝葡胺0.1 mmol/kg,CNR增加超过30%(P≤0.0007)。
  • 钆匹醇0.05 mmol/kg的CNR与钆贝葡胺0.1 mmol/kg相似,差异无统计学意义。
  • 次要终点病灶-脑比值和对比增强百分比的結果与CNR相似。
  • CNR与钆匹醇剂量的关系在所有读者中呈线性。

临床应用与阅片要点

  • 作者结论认为钆匹醇0.05和0.1 mmol/kg两个剂量可考虑用于后续III期研究。
  • 不良反应发生率钆匹醇为11.7%、钆贝葡胺为12.1%,两者相当。
  • 血清肌酐和估算肾小球滤过率较基线变化超过25%的患者在钆匹醇和钆贝葡胺中均少于2%。
  • 血尿素氮和胱抑素C较基线变化在钆匹醇与钆贝葡胺之间也相似。
  • 集中判读心电图未发现安全性问题。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The aim of this study was to determine a safe and effective dose of gadopiclenol, a new high relaxivity macrocyclic gadolinium-based contrast agent. Based on the contrast-to-noise ratio (CNR) as primary criterion, this new agent was compared with gadobenate dimeglumine in patients with contrast-enhancing central nervous system lesions.

METHODS AND MATERIALS: This phase IIb international, multicenter, double-blind, randomized, controlled, parallel dose groups, and cross-over study included adult patients with known or highly suspected lesions with disrupted blood-brain barrier. Patients were randomized to 1 of 4 doses of gadopiclenol (0.025, 0.05, 0.1, 0.2 mmol/kg) and to 1 series of 2 magnetic resonance imaging scans: gadopiclenol then gadobenate dimeglumine at 0.1 mmol/kg or vice versa. The qualitative and quantitative efficacy evaluations were performed by 3 independent off-site blinded readers. Adverse events were monitored up to 1 day after second magnetic resonance imaging.

RESULTS: The study population included 272 patients (58.5% females) with a mean (SD) age of 53.8 (13.6) years. The superiority of gadopiclenol over gadobenate dimeglumine was statistically demonstrated at 0.2 and 0.1 mmol/kg for all readers with an increase in CNR of more than 30% (P ≤ 0.0007). At 0.05 mmol/kg, gadopiclenol showed a CNR of similar magnitude as gadobenate dimeglumine at 0.1 mmol/kg, with no statistically significant difference. Similar results were obtained for lesion-to-brain ratio and contrast enhancement percentage, as secondary criteria. The relationship between CNR and dose of gadopiclenol was linear for all readers. Mean scores for lesion visualization variables, particularly lesion contrast enhancement, tended to be higher with gadopiclenol at 0.1 and 0.2 mmol/kg compared with gadobenate dimeglumine. All 3 readers mainly expressed an overall diagnostic preference for images with gadopiclenol at 0.1 mmol/kg (45.3%, 50.9%, or 86.8% of images) or expressed no preference (49.1%, 49.1%, or 9.4%, respectively), whereas preference for images with gadobenate dimeglumine was reported by 2 readers for 3.8% and 5.7% of the images. Predominantly, no preference was expressed when comparing images with gadopiclenol at 0.05 mmol/kg to those with gadobenate dimeglumine.Rates of adverse reactions were comparable for gadopiclenol (11.7%) and gadobenate dimeglumine (12.1%). Changes from baseline of more than 25% in serum creatinine and estimated glomerular filtration rate occurred in less than 2% of patients equally for gadopiclenol and gadobenate dimeglumine. Changes from baseline for the values of blood urea nitrogen and cystatin C were also similar between gadopiclenol and gadobenate dimeglumine. No safety concerns were detected on centralized electrocardiography readings.

CONCLUSIONS: Between the doses of 0.025 and 0.2 mmol/kg of gadopiclenol, the increase in CNR is linear. Compared with gadobenate dimeglumine at 0.1 mmol/kg, the doses of 0.05 and 0.1 mmol/kg of gadopiclenol gave similar or significantly greater contrast enhancement, respectively, and thus both doses can be considered for future phase III studies.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Bendszus M, Roberts D, Kolumban B, et al. Dose Finding Study of Gadopiclenol, a New Macrocyclic Contrast Agent, in MRI of Central Nervous System. Invest Radiol. 2020. PMID: 31917762. doi:10.1097/RLI.0000000000000624

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。